ReviewAustralian prescriber2016
Prescribing for patients on dialysis.
Review in Australian prescriber, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The use of opioids in cancer patients with renal impairment-a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2017Pooled it
- Changes in Protein Expression of Renal Drug Transporters and Drug-Metabolizing Enzymes in Autosomal Dominant Polycystic Kidney Disease Patients.Clinical pharmacology and therapeutics · 2025Article
- Treatment of insomnia, restless legs, cramps, and pain associated with chronic kidney disease: results from a multinational survey of kidney supportive care practice.BMC nephrology · 2025Article
- Evaluation of Dose Adjustment in Patients With Renal Impairment at Muhimbili National Hospital in Tanzania.Hospital pharmacy · 2024Article
- Prescribing and peritoneal dialysis.Australian prescriber · 2023Review
- Collapsing focal segmental glomerulosclerosis secondary to COVID-19: A systematic review and meta-analysis.Annals of medicine and surgery (2012) · 2023Article
- Antibiotics utilization patterns and dosage appropriateness among patients receiving hemodialysis.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022Article
- Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment.Clinical and molecular hepatology · 2020Article
- When ESKD complicates the management of pain.Seminars in dialysis · 2020Review
- Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety.Clinical pharmacology in drug development · 2019 · on this mapArticle
- Trends in Opioid Prescribing Among Hemodialysis Patients, 2007-2014.American journal of nephrology · 2019Article
- Metformin and patients on dialysis.Australian prescriber · 2016Article
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pharmacokinetics of a drug may be altered in patients with renal impairment who require dialysis. Some drugs are contraindicated. The drug's clearance and therapeutic index determine if a dose adjustment is needed. A lower dose or less frequent dosing may be required. Consult a reference source or the patient's nephrologist before prescribing. Start at a low dose and increase gradually. If possible give once-daily drugs after dialysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.